Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 295

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 295
---
 - $ 298 ) payable to the Company’s officers and directors for fees, expenses, and accrued bonuses and other liabilities.

F-5 7

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 7 | Stockholders’ equity |

Preferred stock

Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |        |   |     |                 |        |   |
|                                                        |     | Numberof shares          |        |   |     | $(in thousands) |        |   |
| Balance - June 30, 2023                                |     |                          | 14,208 |   |     |                 | 10,366 |   |
| Conversion of Series C Preferred stock to common stock |     |                          |   (540 | ) |     |                 |   (393 | ) |
| Balance - December 31, 2023                            |     |                          | 13,668 |   |     |                 |  9,973 |   |

In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of $ 1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are $ 58.00 , $ 60.70 , and $ 57.50 , respectively. Subject to ownership limitations, the owners of the Series C-1 Preferred Stock, the Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10 %, 15 %, 20 % and 25 %, respectively, of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12th, 24th, 36th and 48th month, anniversary of the initial closing of the private placement.